Payment overview · 2025
General Payments
$198.08
12 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel K Pace, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEARCY, AR · NPI 1972567758
Verified facts
What the public records show
CMS Open Payments records show Daniel K Pace, MD received $198.08 in general payments during 2025 across 12 reported records.
GlaxoSmithKline, LLC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.97 | 23.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.40 | 22.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.87 | 18.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.04 | 16.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.01 | 11.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.79 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.08 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.40 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 254 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
254 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 901 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 870 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 661 | 150 |
| Gabapentin | Gabapentin | 501 | 94 |
| Lisinopril | Lisinopril | 442 | 97 |
| Trazodone Hcl | Trazodone Hcl | 435 | 85 |
| Furosemide | Furosemide | 406 | 116 |
| Metformin Hcl | Metformin Hcl | 366 | 78 |
| Losartan Potassium | Losartan Potassium | 361 | 90 |
| Meloxicam | Meloxicam | 356 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 74 |
| Sertraline Hcl | Sertraline Hcl | 332 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 307 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 67 |
| Cefdinir | Cefdinir | 291 | 180 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 255 | 47 |
| Tramadol Hcl | Tramadol Hcl | 255 | 75 |
| Ozempic | Semaglutide | 254 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 247 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 244 | 47 |
| Potassium Chloride | Potassium Chloride | 244 | 52 |
| Glipizide | Glipizide | 239 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 29 |
| Azithromycin | Azithromycin | 213 | 144 |
| Atenolol | Atenolol | 211 | 44 |
| Allopurinol | Allopurinol | 207 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 196 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 184 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 182 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 41 |
| Lorazepam | Lorazepam | 180 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 51 |
| Carvedilol | Carvedilol | 173 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 171 | 36 |
| Simvastatin | Simvastatin | 162 | 31 |
| Pregabalin | Pregabalin | 161 | 23 |
| Donepezil Hcl | Donepezil Hcl | 151 | 29 |
| Finasteride | Finasteride | 151 | 30 |
| Temazepam | Temazepam | 151 | 19 |
| Baclofen | Baclofen | 146 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 26 |
| Buspirone Hcl | Buspirone Hcl | 132 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 43 |
| Eliquis | Apixaban | 126 | 27 |
| Montelukast Sodium | Montelukast Sodium | 125 | 26 |
| Amoxicillin | Amoxicillin | 123 | 99 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 39 |
| Alprazolam | Alprazolam | 118 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 27 |
| Ondansetron Odt | Ondansetron | 114 | 63 |
| Mounjaro | Tirzepatide | 113 | 19 |
| Prednisone | Prednisone | 103 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 17 |
| Diazepam | Diazepam | 95 | 18 |
| Fluconazole | Fluconazole | 91 | 56 |
| Clonazepam | Clonazepam | 89 | 21 |
| Ezetimibe | Ezetimibe | 89 | 20 |
| Primidone | Primidone | 89 | 15 |
| Estradiol | Estradiol | 87 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 83 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 47 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 15 |
| Mirtazapine | Mirtazapine | 79 | 19 |
| Famotidine | Famotidine | 72 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 13 |
| Metformin Hcl Er | Metformin Hcl | 70 | 17 |
| Sucralfate | Sucralfate | 69 | 19 |
| Linzess | Linaclotide | 68 | 18 |
| Levetiracetam | Levetiracetam | 66 | 11 |
| Mupirocin | Mupirocin | 65 | 47 |
| Spironolactone | Spironolactone | 65 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Risperidone | Risperidone | 61 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 11 |
| Celecoxib | Celecoxib | 59 | 14 |
| Ibuprofen | Ibuprofen | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 13 |
| Aripiprazole | Aripiprazole | 52 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Naproxen | Naproxen | 48 | suppressed |
| Nystatin | Nystatin | 48 | 30 |
| Metolazone | Metolazone | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 11 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 40 | 24 |
| Promethazine Hcl | Promethazine Hcl | 40 | 16 |
| Glimepiride | Glimepiride | 39 | 11 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 12 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 31 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 16 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Risperidone Odt | Risperidone | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Ubrelvy | Ubrogepant | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 13 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.08 · 12 records | GlaxoSmithKline, LLC. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, JARDIANCE, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error